<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168949">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897546</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000489213</org_study_id>
    <secondary_id>ECOG-E1L06T1</secondary_id>
    <nct_id>NCT00897546</nct_id>
  </id_info>
  <brief_title>Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma</brief_title>
  <official_title>Multiplex Analysis of Serum Biomarkers for Prediction Interferon Therapy Response in Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the
      laboratory may help doctors learn more about changes that may occur in DNA and identify
      biomarkers related to cancer, and may help doctors learn how well patients will respond to
      treatment.

      PURPOSE: This laboratory study is looking at biomarkers to predict the response to
      interferon therapy in patients with melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Generate a comprehensive multiplexed array of melanoma-associated serological markers
           and validate it using serum samples from patients with melanoma and healthy control
           participants.

        -  Determine changes in the profile of serological markers induced by interferon-alfa 2b
           (IFN-α2b) therapy.

        -  Define panels of serological markers with prognostic and predictive power for IFN-α2b
           therapy responses in patients with melanoma.

      OUTLINE: This is a multicenter study.

      Serum samples are used for multiplex analyses. Biomarkers to be assessed include cytokines,
      chemokines, growth factors, angiogenic and antiangiogenic molecules, matrix metalloproteases
      (MMPs), tissue inhibitors of MMPs (TIMPs), melanoma-associated antigens, basic fibroblast
      growth factor, insulin-like growth factor I and II, thrombospondin, endostatin, angiostatin,
      vasostatin, and vascular endothelial growth factor inhibitor.

      PROJECTED ACCRUAL: A total of 1,716 samples will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Generation of a comprehensive multiplexed array of melanoma-associated serological markers</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the profile of serological markers induced by interferon-alfa 2b therapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Panels of serological markers with prognostic and predictive power for interferon-alfa 2b response</measure>
  </primary_outcome>
  <enrollment type="Anticipated">1716</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of melanoma OR healthy volunteer (control)

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elieser Gorelik, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <results_reference>
    <citation>Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15;13(8):2422-8.</citation>
    <PMID>17438101</PMID>
  </results_reference>
  <verification_date>December 2007</verification_date>
  <lastchanged_date>August 20, 2010</lastchanged_date>
  <firstreceived_date>May 9, 2009</firstreceived_date>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>stage IA melanoma</keyword>
  <keyword>stage IB melanoma</keyword>
  <keyword>stage IIA melanoma</keyword>
  <keyword>stage IIB melanoma</keyword>
  <keyword>stage IIC melanoma</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
